NCT06731023View on ClinicalTrials.gov

Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
HELICOBACTER PYLORI INFECTIONS
Interventions
DRUG

Bismuth

Bismuth 0.6g bid

DRUG

Vonoprazan

vonoprazan 20mg bid

DRUG

Amoxicillin

Amoxicillin 1g bid

DRUG

Rifabutin

Rifabutin 0.15g bid

DRUG

Metronidazole

Metronidazole 400mg qid

DRUG

Other antibiotics

The selection of other antibiotics is based on the results of drug susceptibility testing.

Trial Locations (1)

250012

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Xiuli Zuo

OTHER

NCT06731023 - Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study | Biotech Hunter | Biotech Hunter